Mobilize the immune system to
fight cancer.

Streamlining T-cell engager development
with a diverse panel of fully human
CD3-binding antibodies.

The Opportunity

ANTIBODY MEDICINES CAN BRIDGE THE GAP BETWEEN CANCER AND THE IMMUNE SYSTEM.

Natural immune systems fight cancer with tumor-killing T cells.
But cancer can hide.

CD3 T-cell engagers can:

Bring T cells and cancer cells close together by binding both targets at the same time.

Activate T cell cancer-killing functions by binding to a protein called CD3.

The Challenge

CD3 T-cell engagers have been hard to develop.

It’s hard to strike the right balance.

The CD3-binding arm needs to:

Activate tumor cell killing

Fine-tune cytokine production to limit
unwanted side-effects

It’s hard to find the perfect pair.

The tumor-binding arm needs to:

Specifically bind cancer targets and not healthy tissues

Allow for binding to T cells and cancer cells with the correct geometry

Case Study

Development of a diverse panel of fully human
CD3-binding antibodies.

We used our integrated antibody discovery, characterization, and engineering technologies to develop hundreds of CD3-binding antibodies that are diverse, developable, and validated.

The Solution

STREAMLINE T-CELL ENGAGER DEVELOPMENT.

By integrating our CD3 panel with our antibody discovery and engineering technology, we can rapidly discover T-cell engagers that strike the right balance.